Desferrioxamine (DFO) plus ferrioxamine (FO) variations and alterations in plasma and urinary iron (Fe) levels were investigated in eight children with thalassaemia major during a 12-h s.c. DFO infusion at a dose of 40 mg/kg body weight. During the infusion, blood samples were regularly taken and total urine was also regularly collected in all patients. In the plasma, a mean DFO plus FO plateau level of 9 mg/l was reached after 4 h and remained steady in the subsequent 8 h. At 30 h the mean DFO plus FO concentration in plasma was still 4.5 mg/l. At 30 h, the urinary excretion ranged from 15% to 70% of the infused dose (mean: 42%). In plasma, the Fe concentration increased on average by 20% (range 10%–30%), remained steady during the DFO infusion, then returned to the basal level after 16–24 h. Urinary Fe excretion started early and still persisted 18 h after the infusion. The amount excreted at 30 h ranged from 5 to 27 mg (mean: 13.6 mg). This study emphasizes the delay in obtaining a DFO plus FO plateau in plasma, the important interindividual variations and the slow decrease of the drug after the end of the infusion. It points out the delay and the values of the urinary Fe excretion compared to the plasmatic and urinary drug variations.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Bianco I, Graziani B, Lerone M, Congedo P, Clemente G-F, Ingrao G, Ciccone F, Di Nucci G-D, Mandelli F, Isacchi G (1984) A study of the mechanisms and sites of action of desferrioxamine in thalassemia major. Acta Haematol 71:100–105
Borgna-Pignatti C, De Stefano P, Broglia A-M (1984) Visual loss in a patient on high-dose subcutaneous desferrioxamine. Lancet I:681
Bourdon S, Houze P, Bourdon R (1987) Quantification of desferrioxamine in blood plasma by inductively coupled plasma atomic emission spectrometry. Clin Chem 33:132–134
Cohen A, Schwartz E (1980) Decreasing iron stores during intensive chelation therapy. Ann NY Acad Sci 334:405–408
Davies S-C, Hungerford J-L, Arden G-B, Marcus R-E, Miller M-H, Huehns E-R (1983) Ocular toxicity of high-dose intravenous desferrioxamine. Lancet II:181–184
De Virgiliis S, Argiolu F, Sanna G, Cornacchia G, Cossu P, Cao A, Mallardil V, Puxeddu P (1979) Auditory involvement in thalassemia major. Acta Haematol 61:209–215
De Virgiliis S, Cossu P, Toccafondi C, Sanna G, Frau F, Lobrano R, Cornacchia G, Nucaro A, Loi A, Bertolino F, Cao A (1983) Effect of subcutaneous desferrioxamine on iron balance in young thalassemia major patients. Am J Pediatr Haematol Oncol 5:73–79
Gabutti V, Piga A, Nicola P, Vullo C, Capra L, Di Palma A, Masera G, Terzoli S, Mauri R (1982) Different haemoglobin levels and blood requirement in Cooley's anaemia. Arch Dis Child 2:156–157
Girot R, Thevenin M, Bouveret JP, Jeannel F, Rymer JC (1980) Traitement chélateur du fer dans les surcharges martiales par perfusion sous-cutanée continue de desferrioxamine. Arch Fr Pediatr 37:241–247
Graziano J-H, Markenson A, Miller DR, Chang H, Bestak M, Meyers P, Pisciotto P, Rifkind A (1978) Chelation therapy in β-thalassemia major. I: Intravenous and subcutaneous infusion. J Pediatr 92:648–652
Janka G-E, Mohring P, Helmig M, Haas R-J, Betke K (1981) Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload. Eur J Pediatr 137:285–290
Krüger N, Kijewski H, König R, Tillmann W, Schröter W (1984) Deferoxamin bei Hämosiderose. Dtsch Med Wochenschr 109: 1682–1685
Modell B, Berdoukas V (1984) “The clinical approach to thalassemia”. Grune and Stratton, London, pp 114–134
Modell B, Letsky E-A, Flynn D-M, Peto R, Weatherall D-J (1982) Survival and desferrioxamine in thalassemia major. Br Med J 284:1081–1084
Olivieri N-F, Buncic J-R, Chew E, Gallant T, Harrison R-V, Keenan N, Logan W, Mitchell D, Ricci G, Skarf B, Taylor M, Freedman M-H (1986) Visual and auditory neurotoxicity in patients receiving subcutaneous desferrioxamine infusions. N Engl J Med 314:869–873
Pippard M-J, Callender S-T, Finch C-A (1982) Ferrioxamine excretion in iron-loaded man. Blood 60:286–294
Pippard M-J, Callender S-T, Letsky E-A, Weatherall D-J (1978) Prevention of iron-loading in transfusion dependent thalassemia major. Lancet I:1178–1181
Propper R-D, Cooper B, Rufo R-R, Nienhuis A-W, Anderson W-F, Bunn H-F, Rosenthal A, Nathan D-G (1977) Continuous subcutaneous administration of desferrioxamine in patients with iron overload. N Engl J Med 297:418–423
Rubinstein M, Dupont P, Doppee J-P, Dehon C, Ducobu J, Hainaut J (1985) Ocular toxicity of desferrioxamine. Lancet I: 817–818
Simon P, Ang K-S, Meyrier A, Allain P, Mauras Y (1983) Desferrioxamine, ocular toxicity, and trace metals. Lancet II:512–513
Summers M-R, Jacobs A, Tudway D, Perera P, Ricketts C (1979) Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br J Haematol 42:547–555
About this article
Cite this article
Llados i Vallory, E.A., Girot, R., Lenoir, G. et al. Studies of variations of subcutaneously infused desferrioxamine and iron movements in thalassaemia children. Eur J Pediatr 148, 503–506 (1989). https://doi.org/10.1007/BF00441542
- Chelation therapy